Expert insights. Personalized for you.
29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). The post Is it time for vaccination mandates? MORE
The Pfizer and Moderna vaccines are safe and effective. Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Food and Drug AdministrationFull approval from the F.D.A. will help stop the spread of Covid-19. MORE
IT’S FRIDAY: The Biden administration’s decision to support a temporary waiver of Covid-19 vaccine patents prompted instant and false outrage in pharma. With the new mRNA vaccines made by Pfizer and Moderna, it may take longer. MORE
The EMA has reiterated the benefits of the shot outweigh the risks, but the safety concerns are another hurdle to the vaccine's rollout in Europe MORE
So far, both Pfizer's and Moderna's vaccines appear to work against more transmissible variants, but preparation is underway for the day they don't MORE
Infectious Emerging Diseases Collaboration Disease in the Developing World Epidemiology Infectious/Emerging Diseases Medical/Scientific Ethics Medicine/Health Public Health Vaccines MORE
The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it MORE
The global focus on the development and distribution of COVID-19 vaccines over the past year has been a reminder that there are still many other diseases for which the world has long sought a vaccine. International large-scale vaccine studies. MORE
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. MORE
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake. As I See It COVID Vaccine MORE
SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine. MORE
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine MORE
SUMMARY: Even though the Delta variant of COVID is highly contagious, people are still choosing not to get vaccinated. Concerns about safety, fear of unknown side effects, and misinformation about COVID-19 are some reasons why people may not accept the vaccine. MORE
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?” MORE
You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised. MORE
Highly anticipated results from a Phase 3 study testing the biotech company's shot showed it to be strongly protective and safe, a potential boon for the world's vaccination efforts MORE
A panel of vaccine and infectious disease experts will publicly vet the drugmakers' study results on Thursday. Follow the discussion along with BioPharma Dive reporters here MORE
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com. MORE
The companies aim to deliver 100 million doses per year to 55 African countries in an effort to shrink the wide gap between high- and lower-income countries in coronavirus vaccinations MORE
Buoyed by the success of its COVID-19 vaccine, Moderna has started a phase 1/2 trials of its mRNA-based shot for seasonal influenza, targeting four different flu strains. . They could offer a more potent option to conventional flu shots, according to mRNA vaccine developers. MORE
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday MORE
But the long-term prospects for AstraZeneca's new vaccine business are unclear The company now expects to file for full approval by year’s end and has a variant-specific shot in advanced testing. MORE
SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine MORE
A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments MORE
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year MORE
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots MORE
The agency said the benefits of vaccination with J&J's shot still "clearly outweigh" the risks, which now include very rare cases of a immune-driven condition known as Guillain-Barré MORE
pharmaceutical industry, came out in favor of waiving intellectual property protections for coronavirus vaccines. The Biden administration, siding with some world leaders over the U.S. MORE
Some experts argued falling infection rates might mean vaccination of kids under 12 is unnecessary An advisory panel could not reach consensus on how long or large trials in young children should be. MORE
The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time MORE
The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand MORE
Intranasal vaccination is needle-free and elicits immunity at the site of infection, the respiratory tract Credit: UAB BIRMINGHAM, Ala. MORE
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations MORE
A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine MORE
There are many reasons why people aren’t getting vaccinated. Until we have more data to really understand why people are getting vaccinated against COVID, we shouldn’t fall into the trap of blame. There are potentially many reasons why people haven’t been vaccinated. MORE
GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations GEHA Vaccination Incentive Program Extended to September 6, 2021 LEE’S SUMMIT, Mo.–(BUSINESS MORE
Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent MORE
An interim analysis conducted after 94 cases of COVID-19 in Pfizer and BioNTech's large study found their vaccine to be more than 90% effective MORE
The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials MORE
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses MORE
(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine MORE
Having proved mRNA's might in COVID-19, the biotech company aims to develop similar vaccines for other respiratory illnesses caused by influenza, RSV and metapneumovirus MORE
Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency MORE
The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 100 million doses of Pfizer and BioNTech's vaccine for supply in Europe MORE
Vaccination Related Topics World of DTC Marketing
JULY 20, 2021
29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). The post Is it time for vaccination mandates?
World of DTC Marketing
MARCH 25, 2021
SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
NOVEMBER 16, 2020
SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine
World of DTC Marketing
DECEMBER 11, 2020
(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine
World of DTC Marketing
NOVEMBER 10, 2020
You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised.
World of DTC Marketing
JULY 19, 2021
SUMMARY: Even though the Delta variant of COVID is highly contagious, people are still choosing not to get vaccinated. Concerns about safety, fear of unknown side effects, and misinformation about COVID-19 are some reasons why people may not accept the vaccine.
Bio Pharma Dive
JULY 7, 2021
Having proved mRNA's might in COVID-19, the biotech company aims to develop similar vaccines for other respiratory illnesses caused by influenza, RSV and metapneumovirus
My Local Study
OCTOBER 1, 2020
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com.
World of DTC Marketing
JANUARY 8, 2021
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others.
Bio Pharma Dive
JULY 12, 2021
The agency said the benefits of vaccination with J&J's shot still "clearly outweigh" the risks, which now include very rare cases of a immune-driven condition known as Guillain-Barré
Bio Pharma Dive
JANUARY 25, 2021
The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials
Bio Pharma Dive
NOVEMBER 9, 2020
An interim analysis conducted after 94 cases of COVID-19 in Pfizer and BioNTech's large study found their vaccine to be more than 90% effective
Pharma R&D Today
MAY 18, 2021
The global focus on the development and distribution of COVID-19 vaccines over the past year has been a reminder that there are still many other diseases for which the world has long sought a vaccine. International large-scale vaccine studies.
World of DTC Marketing
JULY 22, 2020
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?”
Scienmag
JULY 23, 2021
Intranasal vaccination is needle-free and elicits immunity at the site of infection, the respiratory tract Credit: UAB BIRMINGHAM, Ala.
Bio Pharma Dive
FEBRUARY 27, 2021
The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time
Bio Pharma Dive
JUNE 14, 2021
Highly anticipated results from a Phase 3 study testing the biotech company's shot showed it to be strongly protective and safe, a potential boon for the world's vaccination efforts
World of DTC Marketing
JULY 28, 2020
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine
Bio Pharma Dive
MAY 10, 2021
The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand
Bio Pharma Dive
FEBRUARY 19, 2021
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday
Bio Pharma Dive
DECEMBER 30, 2020
The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it
Bio Pharma Dive
JULY 31, 2020
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations
Bio Pharma Dive
DECEMBER 9, 2020
A panel of vaccine and infectious disease experts will publicly vet the drugmakers' study results on Thursday. Follow the discussion along with BioPharma Dive reporters here
Bio Pharma Dive
MAY 4, 2021
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year
World of DTC Marketing
AUGUST 3, 2020
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake. As I See It COVID Vaccine
Bio Pharma Dive
JULY 26, 2021
Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent
Bio Pharma Dive
FEBRUARY 24, 2021
Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency
NY Times
MAY 5, 2021
pharmaceutical industry, came out in favor of waiving intellectual property protections for coronavirus vaccines. The Biden administration, siding with some world leaders over the U.S.
NY Times
JULY 1, 2021
The Pfizer and Moderna vaccines are safe and effective. Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Food and Drug AdministrationFull approval from the F.D.A. will help stop the spread of Covid-19.
BioTech 365
JULY 30, 2021
GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations GEHA Vaccination Incentive Program Extended to September 6, 2021 LEE’S SUMMIT, Mo.–(BUSINESS
World of DTC Marketing
MAY 21, 2021
IT’S FRIDAY: The Biden administration’s decision to support a temporary waiver of Covid-19 vaccine patents prompted instant and false outrage in pharma. With the new mRNA vaccines made by Pfizer and Moderna, it may take longer.
Bio Pharma Dive
JANUARY 28, 2021
So far, both Pfizer's and Moderna's vaccines appear to work against more transmissible variants, but preparation is underway for the day they don't
Bio Pharma Dive
FEBRUARY 9, 2021
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots
Scienmag
JULY 16, 2021
Infectious Emerging Diseases Collaboration Disease in the Developing World Epidemiology Infectious/Emerging Diseases Medical/Scientific Ethics Medicine/Health Public Health Vaccines
Pharma Phorum
JULY 8, 2021
Buoyed by the success of its COVID-19 vaccine, Moderna has started a phase 1/2 trials of its mRNA-based shot for seasonal influenza, targeting four different flu strains. . They could offer a more potent option to conventional flu shots, according to mRNA vaccine developers.
Bio Pharma Dive
APRIL 9, 2021
The EMA has reiterated the benefits of the shot outweigh the risks, but the safety concerns are another hurdle to the vaccine's rollout in Europe
Bio Pharma Dive
JUNE 11, 2021
Some experts argued falling infection rates might mean vaccination of kids under 12 is unnecessary An advisory panel could not reach consensus on how long or large trials in young children should be.
Bio Pharma Dive
JULY 21, 2021
The companies aim to deliver 100 million doses per year to 55 African countries in an effort to shrink the wide gap between high- and lower-income countries in coronavirus vaccinations
Bio Pharma Dive
JANUARY 26, 2021
The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 100 million doses of Pfizer and BioNTech's vaccine for supply in Europe
Bio Pharma Dive
APRIL 23, 2021
A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine
Bio Pharma Dive
JANUARY 29, 2021
A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments
World of DTC Marketing
JULY 26, 2021
There are many reasons why people aren’t getting vaccinated. Until we have more data to really understand why people are getting vaccinated against COVID, we shouldn’t fall into the trap of blame. There are potentially many reasons why people haven’t been vaccinated.
Bio Pharma Dive
APRIL 1, 2021
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses
239 
Let's personalize your content